Gritstone bio, Inc.
GRTS
Price:
$0.0322
Market Cap:
$3.80M
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine pl...[Read more]
Industry
Biotechnology
IPO Date
2018-09-28
Stock Exchange
NASDAQ
Ticker
GRTS
PE Ratio
[-0.03]
ROE
[-328.51%]
Current Ratio
[2.54]
Dividend Yield
[0%]
Enterprise Value
[54.12M]
Dividend History
The ROE as of December 2024 (TTM) for Gritstone bio, Inc. (GRTS) is -328.51%
According to Gritstone bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -328.51%. This represents a change of 159.67% compared to the average of -126.51% of the last 4 quarters.
Gritstone bio, Inc. (GRTS) Historical ROE (quarterly & annually)
How has GRTS ROE performed in the past?
The mean historical ROE of Gritstone bio, Inc. over the last ten years is -78.67%. The current -328.51% ROE has changed 317.55% with respect to the historical average. Over the past ten years (40 quarters), GRTS's ROE was at its highest in in the March 2021 quarter at 3.97%. The ROE was at its lowest in in the March 2024 quarter at -289.21%.
Average
-78.67%
Median
-53.86%
Minimum
-267.10%
Maximum
-34.69%
Gritstone bio, Inc. (GRTS) ROE by Quarter and Year
Discovering the peaks and valleys of Gritstone bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 303.22%
Maximum Annual ROE = -34.69%
Minimum Annual Increase = -44.71%
Minimum Annual ROE = -267.10%
| Year | ROE | Change |
|---|---|---|
| 2023 | -267.10% | 303.22% |
| 2022 | -66.24% | 90.96% |
| 2021 | -34.69% | -44.71% |
| 2020 | -62.74% | -7.30% |
| 2019 | -67.68% | 55.81% |
| 2018 | -43.44% | 2.13% |
| 2017 | -42.53% | -5.43% |
Gritstone bio, Inc. (GRTS) Average ROE
How has GRTS ROE performed in the past?
The current ROE of Gritstone bio, Inc. (GRTS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-122.68%
5-year avg
-99.69%
10-year avg
-78.67%
Gritstone bio, Inc. (GRTS) ROE vs. Peers
How is GRTS’s ROE compared to its peers?
Gritstone bio, Inc.’s ROE is greater than Aurinia Pharmaceuticals Inc. (-6.05%), less than BridgeBio Pharma, Inc. (37.14%), less than Annovis Bio, Inc. (874.76%), less than ImmunoGen, Inc. (5.04%), greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Kezar Life Sciences, Inc. (-59.73%), greater than Fulcrum Therapeutics, Inc. (-7.31%), greater than Passage Bio, Inc. (-72.53%), greater than InflaRx N.V. (-65.54%), greater than Allogene Therapeutics, Inc. (-58.07%), less than G1 Therapeutics, Inc. (26.28%), less than Heron Therapeutics, Inc. (76.79%), greater than Annexon, Inc. (-38.99%), greater than Sangamo Therapeutics, Inc. (-266.47%), greater than Affimed N.V. (-193.85%), greater than Leap Therapeutics, Inc. (-116.24%), greater than Adaptimmune Therapeutics plc (-74.84%), greater than Corvus Pharmaceuticals, Inc. (-167.55%), less than Aptose Biosciences Inc. (1.03%),
| Company | ROE | Market cap |
|---|---|---|
| -6.05% | $1.29B | |
| 37.14% | $5.39B | |
| 874.76% | $69.12M | |
| 5.04% | $8.73B | |
| -104.85% | $71.47M | |
| -64.55% | $57.32M | |
| -42.26% | $726.61M | |
| -42.45% | $273.18M | |
| -26.83% | $2.80B | |
| -59.73% | $47.86M | |
| -7.31% | $245.42M | |
| -72.53% | $40.24M | |
| -65.54% | $147.80M | |
| -58.07% | $438.21M | |
| 26.28% | $377.75M | |
| 76.79% | $240.31M | |
| -38.99% | $557.49M | |
| -266.47% | $521.62M | |
| -193.85% | $18.88M | |
| -116.24% | $111.51M | |
| -74.84% | $148.11M | |
| -167.55% | $314.86M | |
| 1.03% | $14.88M |
Build a custom stock screener for Gritstone bio, Inc. (GRTS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gritstone bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Gritstone bio, Inc. (GRTS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Gritstone bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Gritstone bio, Inc.'s ROE?
How is the ROE calculated for Gritstone bio, Inc. (GRTS)?
What is the highest ROE for Gritstone bio, Inc. (GRTS)?
What is the 3-year average ROE for Gritstone bio, Inc. (GRTS)?
What is the 5-year average ROE for Gritstone bio, Inc. (GRTS)?
How does the current ROE for Gritstone bio, Inc. (GRTS) compare to its historical average?